Get the Stockscreener App
2.20
0.90%
-0.02
After Hours:
2.08
-0.12
-5.45%
Scisparc Ltd stock is traded at $2.20, with a volume of 432.49K.
It is down -0.90% in the last 24 hours and down -40.22% over the past month.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$2.22
Open:
$2.15
24h Volume:
432.49K
Relative Volume:
0.08
Market Cap:
$1.18M
Revenue:
$1.31M
Net Income/Loss:
$-7.47M
P/E Ratio:
-0.3051
EPS:
-7.2117
Net Cash Flow:
$-5.11M
1W Performance:
-8.71%
1M Performance:
-40.22%
6M Performance:
+603.10%
1Y Performance:
+898.64%
1-Day Range:
$2.07
$2.40
1-Week Range:
$2.07
$3.3199
52-Week Range:
$0.197
$8.90
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
2.20 | 3.60M | 1.31M | -7.47M | -5.11M | -7.2117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. (SPRC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
SciSparc Ltd. Announces $2.2 Million Securities Offering - The Globe and Mail
Form 424B5 SciSparc Ltd. - StreetInsider
Is SciSparc Ltd a good long term investmentStock Buyback Announcements & Free Tap Rapid Wealth - earlytimes.in
What analysts say about SciSparc Ltd stockMid Cap Growth Trends & Minimal Investment Trading Tips - earlytimes.in
SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech - Stocktwits
SciSparc’s Stock Slip: Investment Opportunity? - timothysykes.com
SciSparc Ltd. to Acquire Xylo’s Patents for Endoscopic Systems - TipRanks
SciSparc’s Patent Surge: Buy or Hold? - StocksToTrade
SciSparc Ltd. (SPRC) Stock: Jumps as Company Expands into High-Growth GERD Device Market - parameter.io
Why SciSparc Stock Is Gaining Today - Benzinga
SciSparc to acquire endoscopic system patents from Xylo Technologies By Investing.com - Investing.com Nigeria
SciSparc Shares Surge After Company Moves to Acquire GERD Treatment Technology - MSN
SciSparc Stocks Surge: A Strategic Leap Forward? - timothysykes.com
SciSparc to acquire MUSE endoscopic system patents from Xylo By Investing.com - Investing.com Nigeria
SciSparc stock soars after acquiring GERD treatment technology By Investing.com - Investing.com Nigeria
SciSparc stock soars after acquiring GERD treatment technology - Investing.com
SciSparc to acquire treasury of patents for medical endoscopy systems - TipRanks
Scisparc to acquire treasury of patents for innovative medical endoscopy systems - MarketScreener
Scisparc shares climb 27.5% premarket; co says will buy a treasury of patents, trademarks and intellectual property rights from Xylo - MarketScreener
SciSparc Ltd. Signs Agreement to Acquire Patent and Intellectual Property Portfolio for Innovative MUSE™ Endoscopic System from Xylo Technologies Ltd. - Quiver Quantitative
SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems - 富途牛牛
SciSparc Ltd. entered into a binding term sheet to acquire Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd from Xylo Technologies Ltd. - MarketScreener
SciSparc, Clearmind Medicine file Israeli patent application for depression - MSN
Will SciSparc Ltd. stock recover faster than peersGlobal Markets & Risk Managed Investment Signals - newser.com
How SciSparc Ltd. stock compares to industry benchmarksJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - newser.com
SciSparc Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
SciSparc Announces New Patent Filing for Depression Treatment - TipRanks
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
[6-K] SciSparc Ltd. Current Report (Foreign Issuer) | SPRC SEC FilingForm 6-K - Stock Titan
SciSparc subsidiary files patent for depression treatment combination By Investing.com - Investing.com Australia
SciSparc subsidiary files patent for depression treatment combination - Investing.com
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression - The Manila Times
SciSparc Ltd. Partner NeuroThera Labs Advances Depression Treatment with New Patent Application for Combination Therapy - Quiver Quantitative
SciSparc: Neurothera Labs Announces Israeli Patent - GlobeNewswire
Will SciSparc Ltd. stock gain from lower inflationWeekly Profit Summary & Weekly High Potential Stock Alerts - newser.com
Is SciSparc Ltd. stock entering bullish territoryJuly 2025 Selloffs & Verified Trade Idea Suggestions - newser.com
Is SciSparc Ltd. stock in correction or buying zone2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
Is SciSparc Ltd. stock a top momentum playMarket Risk Summary & Capital Efficient Trading Techniques - newser.com
SciSparc Ltd. Releases Interim Financial Results for H1 2025 - MSN
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):